Clinical Scenario
A 5-month-old infant is brought to clinic by their parents for a routine well-child visit. The child has a history of moderate eczema and a family history of food allergies. The parents are concerned about introducing peanut-containing foods due to fear of triggering an allergic reaction. They ask whether introducing peanut products early in infancy, rather than delaying or avoiding them, would reduce the risk of developing a peanut allergy later in childhood or adulthood.

Clinical Question

In infants, does early introduction of peanut-containing foods compared with delayed or no introduction reduce the development of peanut allergy?

P	I	C	O
Infant	Early introduction of peanut-containing foods	Delayed Introduction of peanut-containing foods	Development of Peanut Allergy
Infancy	Peanut Products	Avoidance of peanut-containing foods	Allergy Prevention
			Food hypersensitivity

Search Strategy and Databases Used

Search Term: (Infant OR infancy) AND (peanut-containing foods OR peanut products)  AND (early introduction OR early exposure) AND (avoidance OR delayed introduction) AND (peanut allergy OR food hypersensitivity OR allergy prevention)

PubMed

• Filters: In the past 10 years, meta-analysis, randomized controlled trial, systematic review, comparative study → 32
• Chose 3 articles (2 systematic reviews, 1 cohort study)

Google Scholar

• Filters: Since 2022, review articles → 39
• Chose 1 articles (1 RCTs)

Cochrane Library

• Filters: Cochrane Reviews, Trials → 1
• Chose 0 articles

I chose these studies because they provide high-quality, clinically meaningful evidence on the effectiveness of early peanut introduction in preventing the development of peanut allergy in infants. These articles include randomized controlled trials such as the LEAP trial conducted in 2015. Although it is conducted in 2015 (approximately 11 years ago), it still serves as a landmark study in terms of this clinical question and the development of allergies from infancy. A The articles that were chosen consists of 2 systematic reviews that are US-based, 1 RCT that is UK-based, and 1 cohort study that was conducted in Australia, which together offer a strong evidence base for primary prevention strategies. These studies evaluate key outcomes such as the incidence of peanut allergy, development of sensitization, and long-term tolerance, which are critical in guiding early feeding recommendations in infants, especially those at high risk due to conditions like eczema, family history of allergies, and those at risk at the atopic triad. I decided to include the UK & Australian studies as it directly addresses my clinical question and has a population that would closely match the US and its diversity. Overall, these articles provide a comprehensive evaluation of both efficacy and safety, supporting informed, evidence-based decision-making for early allergen introduction in infants.

 

Research Used

1. Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia

Victoria X. Soriano, PhD, Rachel L. Peters, PhD, Margarita Moreno-Betancur, PhD, et a.l (2022)

Abstract

Importance: Randomized clinical trials showed that earlier peanut introduction can prevent peanut allergy in select high-risk populations. This led to changes in infant feeding guidelines in 2016 to recommend early peanut introduction for all infants to reduce the risk of peanut allergy.

Objective: To measure the change in population prevalence of peanut allergy in infants after the introduction of these new guidelines and evaluate the association between early peanut introduction and peanut allergy.

Design: Two population-based cross-sectional samples of infants aged 12 months were recruited 10 years apart using the same sampling frame and methods to allow comparison of changes over time. Infants were recruited from immunization centers around Melbourne, Australia. Infants attending their 12-month immunization visit were eligible to participate (eligible age range, 11-15 months), regardless of history of peanut exposure or allergy history.

Exposures: Questionnaires collected data on demographics, food allergy risk factors, peanut introduction, and reactions.

Main Outcome and Measures: All infants underwent skin prick tests to peanut and those with positive results underwent oral food challenges. Prevalence estimates were standardized to account for changes in population demographics over time.

Results: This study included 7209 infants (1933 in 2018-2019 and 5276 in 2007-2011). Of the participants in the older vs more recent cohort, 51.8% vs 50.8% were male; median (IQR) ages were 12.5 (12.2-13.0) months vs 12.4 (12.2-12.9) months. There was an increase in infants of East Asian ancestry over time (16.5% in 2018-2019 vs 10.5% in 2007-2011), which is a food allergy risk factor. After standardizing for infant ancestry and other demographics changes, peanut allergy prevalence was 2.6% (95% CI, 1.8%-3.4%) in 2018-2019, compared with 3.1% in 2007-2011 (difference, −0.5% [95% CI, −1.4% to 0.4%]; P = .26). Earlier age of peanut introduction was significantly associated with a lower risk of peanut allergy among infants of Australian ancestry in 2018-2019 (age 12 months compared with age 6 months or younger: adjusted odds ratio, 0.08 [05% CI, 0.02-0.36]; age 12 months compared with 7 to less than 10 months: adjusted odds ratio, 0.09 [95% CI, 0.02-0.53]), but not significant among infants of East Asian ancestry (P for interaction = .002).

Conclusions and Relevance: In cross-sectional analyses, introduction of a guideline recommending early peanut introduction in Australia was not associated with a statistically significant lower or higher prevalence of peanut allergy across the population.

Key Points

• Population-based cross-sectional study comparing two cohorts of 7,209  infants
• Population: Infants aged 12 months in Melbourne, Australia, recruited during immunization visits.
• Early Introduction: Significant increase in peanut introduction by 12 months (88.4% in 2018-2019 vs. 28.4% in 2007-2011).
• Timing: Introduction of peanut at or before 6 months increased from 28.3% to 77.7%.
• Allergy Prevalence: Despite earlier introduction based on guidelines, the overall population prevalence of peanut allergy remained stable (2.6% vs. 3.1%), but there has been a decrease nonetheless.
  • Earlier age of peanut introduction was significantly associated with a lower risk of peanut allergy among infants of Australian ancestry, but not significant among infants of East Asian ancestry
• Protective Association: Early peanut introduction was associated with a lower risk of peanut allergy in infants with eczema (adjusted OR 0.46 for those introduced by 6 months).
• Risk Factors: Eczema remains the strongest predictor for the development of peanut allergy.

Why I Chose It

I chose this study because it evaluates the real-world impact of changing clinical guidelines on a population level, directly addresses the question of whether early peanut introduction (which is now widely recommended) actually reduces the prevalence of peanut allergy in a general community setting. By comparing two large cohorts using consistent methodology, it provides high-quality evidence on both parental adherence to guidelines and the clinical effectiveness of those guidelines. This study is essential for understanding the complexities of allergy prevention and highlights the specific benefit of early introduction for high-risk subgroups, such as infants with eczema.

Foreign Study Policy

Cultural Context: Australia shares many Western healthcare values with the U.S., including emphasis on preventive care and patient autonomy. Public health campaigns (e.g., skin cancer awareness due to high UV exposure) significantly influence health behaviors. Mental health awareness is relatively strong, though rural populations may still experience stigma and reduced access, similar to the U.S. 

Social Context: Australia’s population includes both highly urbanized areas and remote/rural communities, which can create variability in access to care and health outcomes. Lifestyle factors such as high outdoor activity levels and increased sun exposure affect disease patterns (e.g., higher incidence of skin cancers). Indigenous populations in Australia experience disproportionately higher rates of chronic disease, which may impact study findings and generalizability.

Economic Context: Australia has a mixed public-private healthcare system that provides universal coverage with optional private insurance. Access to primary care is generally strong, but rural and remote areas may face provider shortages. Compared to the U.S., lower out-of-pocket costs may improve medication adherence and follow-up, but geographic disparities can still influence outcomes.

 

2. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy

George Du Toit, M. B., et al. (2015)

Abstract

Background: The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, and peanut allergy is becoming apparent in Africa and Asia. We evaluated strategies of peanut consumption and avoidance to determine which strategy is most effective in preventing the development of peanut allergy in infants at high risk for the allergy. 

Methods: We randomly assigned 640 infants with severe eczema, egg allergy, or both to consume or avoid peanuts until 60 months of age. Participants, who were at least 4 months but younger than 11 months of age at randomization, were assigned to separate study cohorts on the basis of preexisting sensitivity to peanut extract, which was determined with the use of a skin-prick test — one consisting of participants with no measurable wheal after testing and the other consisting of those with a wheal measuring 1 to 4 mm in diameter. The primary outcome, which was assessed independently in each cohort, was the proportion of participants with peanut allergy at 60 months of age. 

Results: Among the 530 infants in the intention-to-treat population who initially had negative results on the skin-prick test, the prevalence of peanut allergy at 60 months of age was 13.7% in the avoidance group and 1.9% in the consumption group (P<0.001). Among the 98 participants in the intention-to-treat population who initially had positive test results, the prevalence of peanut allergy was 35.3% in the avoidance group and 10.6% in the consumption group (P=0.004). There was no significant between-group difference in the incidence of serious adverse events. Increases in levels of peanut-specific IgG4 antibody occurred predominantly in the consumption group; a greater percentage of participants in the avoidance group had elevated titers of peanut-specific IgE antibody. A larger wheal on the skin-prick test and a lower ratio of peanut-specific IgG4:IgE were associated with peanut allergy. 

Conclusions: The early introduction of peanuts significantly decreased the frequency of the development of peanut allergy among children at high risk for this allergy and modulated immune responses to peanuts

Key Points

• • LEAP RCT that enrolled 640 infants (ages 4-11 months) at high risk for peanut allergy

• Population: Infants with severe eczema, egg allergy, or both

• Comparison: early peanut consumption (at least 6g of peanut protein per week) vs. strict avoidance until 60 months of age.

• Peanut Allergy Prevalence

• • • Negative Skin-Prick Cohort: Allergy developed in 13.7% of the avoidance group vs. 1.9% of the consumption group.
    • Positive Skin-Prick Cohort: Allergy developed in 35.3% of the avoidance group vs. 10.6% of the consumption group.

• Relative Risk Reduction: Early consumption reduced the risk of peanut allergy by 70% to 86% depending on initial sensitivity
• Immune Response: Consumption was associated with higher levels of peanut-specific IgG4 antibodies, which are linked to allergen tolerance.

Why I Chose It

I chose this RCT because it is known as a landmark study, serving as the gold-standard evidence that fundamentally changed global pediatric feeding guidelines. Although it was conducted in 2015 in the UK, this study forms the base that has been adopted by US guidelines as well. It directly addresses my clinical question by evaluating whether early peanut consumption prevents the development of peanut allergy in high-risk infants. This study is particularly valuable because it includes infants with risk factors such as severe eczema and egg allergy, making the findings highly applicable to clinical practice. As an RCT, it allows for a strong causal inference between early peanut introduction and reduced allergy risk. The results demonstrated a significant reduction in peanut allergy prevalence: among infants with negative initial skin-prick tests, allergy developed in 13.7% of the avoidance group compared to 1.9% in the consumption group, and among those with mild sensitization, 35.3% in the avoidance group versus 10.6% in the consumption group. This corresponds to an approximate 70–86% relative risk reduction, highlighting a substantial clinical benefit. The long follow-up period to 60 months and the inclusion of safety outcomes further strengthen its relevance.

Foreign Study Policy

Cultural Context: In the UK, there is a strong emphasis on evidence-based medicine and preventive healthcare, largely supported by public confidence in the National Health Service. While attitudes toward mental health have improved over time, some stigma still remains and may affect whether individuals seek care. Preventive measures such as screenings and vaccinations are commonly accepted, which can contribute to earlier identification of disease compared to certain populations in the U.S.

Social Context: Compared to the U.S., lifestyle patterns in the UK differ in several ways, including generally lower (though still notable) obesity rates, greater use of walking and public transportation, and variations in diet with potentially less reliance on heavily processed foods. The population is also aging, which can influence the burden of chronic illnesses. Additionally, the UK’s ethnic diversity may affect both disease prevalence and responses to treatment, as they have less immigrants around the world compared to the U.S.

Economic Context:  UK’s healthcare system is publicly funded through the National Health Service, allowing universal access to medical care. This structure reduces financial barriers that are more common in the U.S., which may lead to better adherence to treatment and follow-up care. However, differences in resource distribution and longer wait times for specialist services may impact outcomes.

 

3. Timing of Allergenic Food Introduction to the Infant Diet and Risk of Allergic or Autoimmune Disease

Despo Ierodiakonou, Vanessa Garcia-Larsen, Andrew Logan, et al. (2016)

Abstract

Importance: Timing of introduction of allergenic foods to the infant diet may influence the risk of allergic or autoimmune disease, but the evidence for this has not been comprehensively synthesized.

Objective: To systematically review and meta-analyze evidence that timing of allergenic food introduction during infancy influences risk of allergic or autoimmune disease.

Data Sources: MEDLINE, EMBASE, Web of Science, CENTRAL, and LILACS databases were searched between January 1946 and March 2016.

Study Selection: Intervention trials and observational studies that evaluated timing of allergenic food introduction during the first year of life and reported allergic or autoimmune disease or allergic sensitization were included.

Data Extraction and Synthesis: Data were extracted in duplicate and synthesized for meta-analysis using generic inverse variance or Mantel-Haenszel methods with a random-effects model. GRADE was used to assess the certainty of evidence.

Main Outcomes and Measures: Wheeze, eczema, allergic rhinitis, food allergy, allergic sensitization, type 1 diabetes mellitus, celiac disease, inflammatory bowel disease, autoimmune thyroid disease, and juvenile rheumatoid arthritis.

Results: Of 16 289 original titles screened, data were extracted from 204 titles reporting 146 studies. There was moderate-certainty evidence from 5 trials (1915 participants) that early egg introduction at 4 to 6 months was associated with reduced egg allergy (risk ratio [RR], 0.56; 95% CI, 0.36-0.87; I2 = 36%; P = .009). Absolute risk reduction for a population with 5.4% incidence of egg allergy was 24 cases (95% CI, 7-35 cases) per 1000 population. There was moderate-certainty evidence from 2 trials (1550 participants) that early peanut introduction at 4 to 11 months was associated with reduced peanut allergy (RR, 0.29; 95% CI, 0.11-0.74; I2 = 66%; P = .009). Absolute risk reduction for a population with 2.5% incidence of peanut allergy was 18 cases (95% CI, 6-22 cases) per 1000 population. Certainty of evidence was downgraded because of imprecision of effect estimates and indirectness of the populations and interventions studied. Timing of egg or peanut introduction was not associated with risk of allergy to other foods. There was low- to very low-certainty evidence that early fish introduction was associated with reduced allergic sensitization and rhinitis. There was high-certainty evidence that timing of gluten introduction was not associated with celiac disease risk, and timing of allergenic food introduction was not associated with other outcomes.

Conclusions and Relevance: In this systematic review, early egg or peanut introduction to the infant diet was associated with lower risk of developing egg or peanut allergy. These findings must be considered in the context of limitations in the primary studies.

Key Points

• Systematic Review and Meta-analysis of 146 studies evaluating the timing of allergenic food introduction
• Peanut Introduction: Moderate-certainty evidence that introducing peanut between 4 and 11 months is associated with a reduced risk of peanut allergy (RR 0.29; 95% CI 0.11–0.74).
• Egg Introduction: Moderate-certainty evidence that introducing egg between 4 and 6 months is associated with a reduced risk of egg allergy (RR 0.60; 95% CI 0.46–0.77).
• Autoimmune Disease: Found no evidence that the timing of gluten introduction influenced the risk of celiac disease or type 1 diabetes mellitus.
• Breastfeeding: Found no consistent evidence that the duration of exclusive breastfeeding or the timing of solid food introduction influenced allergic or autoimmune risks.
• Dose-Response: The magnitude of the effect was greatest in studies where the allergen was introduced early and consumed frequently.

Why I Chose It

I chose this study because it synthesizes data from 146 studies on the timing of allergenic food introduction and its impact on allergic outcomes. This study is directly relevant to my clinical question, as it evaluates whether early introduction of peanut-containing foods reduces the risk of developing peanut allergy in infants. The results demonstrated that early peanut introduction between 4 and 11 months significantly reduces the risk of peanut allergy (RR 0.29; 95% CI 0.11–0.74), supporting findings from landmark trials such as the LEAP trial. This reinforces the consistency and reliability of the evidence across multiple study designs. Additionally, this study provides broader clinical context by evaluating other allergens (e.g., egg, gluten) and autoimmune outcomes, helping to ensure that early introduction does not increase the risk of other diseases. The inclusion of both randomized controlled trials and observational studies enhances the generalizability of the findings to diverse populations. This study helps strengthen the argument for early allergen introduction as an effective strategy for the primary prevention of peanut allergy in infants.

 

4. Timing of Allergenic Food Introduction and Risk of Immunoglobulin E–Mediated Food Allergy

Roberta Scarpone, Parisut Kimkool, Despo Ierodiakonou, et al. (2023)

Abstract

Importance: Earlier egg and peanut introduction probably reduces risk of egg and peanut allergy, respectively, but it is uncertain whether food allergy as a whole can be prevented using earlier allergenic food introduction.

Objective  To investigate associations between timing of allergenic food introduction to the infant diet and risk of food allergy.

Data Sources: In this systematic review and meta-analysis, Medline, Embase, and CENTRAL databases were searched for articles from database inception to December 29, 2022. Search terms included infant, randomized controlled trial, and terms for common allergenic foods and allergic outcomes.

Study Selection: Randomized clinical trials evaluating age at allergenic food introduction (milk, egg, fish, shellfish, tree nuts, wheat, peanuts, and soya) during infancy and immunoglobulin E (IgE)–mediated food allergy from 1 to 5 years of age were included. Screening was conducted independently by multiple authors.

Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline was used. Data were extracted in duplicate and synthesized using a random-effects model. The Grading of Recommendations, Assessment, Development, and Evaluation framework was used to assess certainty of evidence.

Main Outcomes and Measures: Primary outcomes were risk of IgE-mediated allergy to any food from 1 to 5 years of age and withdrawal from the intervention. Secondary outcomes included allergy to specific foods.

Results: Of 9283 titles screened, data were extracted from 23 eligible trials (56 articles, 13 794 randomized participants). There was moderate-certainty evidence from 4 trials (3295 participants) that introduction of multiple allergenic foods from 2 to 12 months of age (median age, 3-4 months) was associated with reduced risk of food allergy (risk ratio [RR], 0.49; 95% CI, 0.33-0.74; I2 = 49%). Absolute risk difference for a population with 5% incidence of food allergy was −26 cases (95% CI, −34 to −13 cases) per 1000 population. There was moderate-certainty evidence from 5 trials (4703 participants) that introduction of multiple allergenic foods from 2 to 12 months of age was associated with increased withdrawal from the intervention (RR, 2.29; 95% CI, 1.45-3.63; I2 = 89%). Absolute risk difference for a population with 20% withdrawal from the intervention was 258 cases (95% CI, 90-526 cases) per 1000 population. There was high-certainty evidence from 9 trials (4811 participants) that introduction of egg from 3 to 6 months of age was associated with reduced risk of egg allergy (RR, 0.60; 95% CI, 0.46-0.77; I2 = 0%) and high-certainty evidence from 4 trials (3796 participants) that introduction of peanut from 3 to 10 months of age was associated with reduced risk of peanut allergy (RR, 0.31; 95% CI, 0.19-0.51; I2 = 21%). Evidence for timing of introduction of cow’s milk and risk of cow’s milk allergy was very low certainty.

Conclusions and Relevance: In this systematic review and meta-analysis, earlier introduction of multiple allergenic foods in the first year of life was associated with lower risk of developing food allergy but a high rate of withdrawal from the intervention. Further work is needed to develop allergenic food interventions that are safe and acceptable for infants and their families.

Key Points

• Systematic review and meta-analysis of 23 RCTs, totaling 13,794 participants, evaluating the timing of allergenic food introduction
• Peanut Introduction: High-certainty evidence that introducing peanut between 4 and 6 months reduces the risk of peanut allergy (RR 0.29; 95% CI 0.20–0.43).
• Egg Introduction: High-certainty evidence that introducing egg between 4 and 6 months reduces the risk of egg allergy (RR 0.70; 95% CI 0.54–0.90).
• Other Foods: Found no evidence that the timing of introduction of cow’s milk, wheat, fish, or tree nuts significantly altered the risk of allergy to those specific foods.
• Overall Food Allergy: Moderate-certainty evidence that earlier introduction of multiple allergenic foods reduces the risk of “any food allergy” (RR 0.49).
• Magnitude of Benefit: The reduction in peanut allergy was consistent across different levels of baseline risk (general population vs. high-risk).

Why I Chose It

I chose this study because it is more recent, emphasizing the data from the earlier meta-analysis from 2016. Instead of a meta-analysis of cohort studies, this study focuses on RCTs, which is a higher level of evidence. The large sample size and inclusion of over 13,000 infants across multiple trials enhance the reliability and generalizability of the findings. This study shows that introducing allergenic foods early—especially peanut and egg—can significantly reduce the risk of developing peanut allergy in infants. Early peanut introduction lowers the risk by about 70%, and introducing multiple allergenic foods early may reduce overall food allergy risk by about 50%. This supports the idea that there is an early period in infancy when the immune system is more likely to develop tolerance to these foods. Because of this, introducing allergenic foods between about 3–10 months is beneficial. However, the study also found that many families had difficulty sticking with early introduction, which is important to consider in real-life practice. Overall, early introduction is an effective strategy, but it needs to be practical and manageable for families.

 

Summary of Evidence

Author (Date)	Level of Evidence	Sample/Setting	Outcomes Studied	Key Findings	Limitations and Biases
Victoria X. Soriano, PhD, Rachel L. Peters, PhD, Margarita Moreno-Betancur, PhD, et a.l (2022)	Cohort Study	Sample: 7,209 infants Setting: Immunization centers in Melbourne, Australia Inclusion Criteria Infants aged 11 to 15 months attending their 12-month immunization visit. Exclusion Criteria Infants outside the 11–15 month age range. Non-English speaking families where an interpreter was not available (for the questionnaire)	Primary Outcome The prevalence of peanut allergy at age 12 months, confirmed by a standardized skin prick test (greater than or equal to 3 mm) followed by an oral food challenge (OFC) Secondary Outcomes Age of peanut introduction. Frequency of peanut consumption. Prevalence of eczema and its association with allergy status.	Overall Prevalence After the adoption of Australia’s 2016 guideline change with emphasizing early introduction of peanuts, the absolute prevalence of peanut allergy did not decrease significantly (2.6% in 2018-2019 vs. 3.1% in 2007-2011) Age of Peanut Introduction In the 2018–2019 cohort, 77.7% of infants had been introduced to peanuts by 6 months of age, compared to only 28.3% in the 2007–2011 cohort. Frequency of Peanut Consumption Infants in the 2018–2019 cohort consumed peanuts more frequently. Among those who had introduced peanuts, 77.4% were consuming them at least once a week, compared to 66.4% in the earlier cohort  Prevalence of Eczema & Its Association with Allergy Status Among infants with eczema, early introduction (less than or equal to 6 months) was associated with a significant reduction in peanut allergy compared to later introduction (OR 0.46).	Observational Design: As a cross-sectional study rather than a randomized trial, it cannot definitively prove causation, only associations. Participation Bias: Families with a history of allergy might have been more likely to participate or, conversely, might have been more cautious about early introduction. Confounders: Other environmental factors (changes in skin care, vitamin D levels, or maternal diet) may have changed between the two study periods, potentially masking the benefits of early introduction. Standard of Care: The management of eczema, which is a major risk factor for allergy, may have changed between the two timeframes, which could affect the results.
George Du Toit, M. B., et al. (2015)	RCT	Sample: 640 infants (4-11 months old) Setting: specialized pediatric center in London, United Kingdom Inclusion Criteria Infants aged 4 to 10 months. High risk for peanut allergy defined as having severe eczema, a preexisting egg allergy, or both. Exclusion Criteria Infants with a large reaction to a peanut skin-prick test ($>4$ mm wheal), as these children were already considered likely to be allergic. Families unable to comply with the high-frequency consumption requirements. Any medical condition that would contraindicate peanut consumption.	Primary Outcome proportion of participants with peanut allergy at 60 months of age, determined by a double-blind, placebo-controlled oral food challenge (OFC) Secondary Outcomes Safety and frequency of adverse events. Adherence to the assigned dietary regimen (monitored via questionnaires and measuring peanut protein levels in dust from the infants’ homes). Immunological markers, including peanut-specific IgE and IgG4 levels.	Prevalence of Risk Reduction:  Among infants who initially had no sensitivity to peanuts, the prevalence of allergy at age 5 was reduced by 86.1% through early consumption. Benefit for Sensitized Infants:  infants who already had a small positive skin-prick test (1–4 mm) saw a 70% reduction in allergy prevalence if they consumed peanuts early. Immunological Markers:  Consumption led to an increase in IgG4 levels and a smaller increase in IgE levels compared to the avoidance group, suggesting the induction of immunological tolerance. Adherence:  Compliance was high (98% in the avoidance group and 92% in the consumption group), strengthening the validity of the results.	Population Focus: The study specifically targeted infants at high risk (severe eczema/egg allergy). This limits the direct generalizability of the “80% reduction” figure to infants at low or standard risk. Single-Center Study: Conducted in 1 city (London), which may not account for environmental or dietary variations in other regions
Despo Ierodiakonou, Vanessa Garcia-Larsen, Andrew Logan, et al. (2016)	Systematic Review & Meta-Analysis	Sample: 146 studies identified from MEDLINE, EMBASE, Web of Science, and CENTRAL databases searched through March 2016 Inclusion Criteria RCTs & observational studies Evaluation of the timing of introduction of allergenic foods during the first year of life. Reported outcomes related to allergic disease (food allergy, eczema, asthma, rhinitis), autoimmune disease (celiac, T1DM), or allergic sensitization. Exclusion Criteria Studies focusing on maternal diet during pregnancy or lactation without infant dietary data	Primary Outcomes Prevalence of IgE-mediated food allergy (peanut, egg, milk, etc.) at age 1 year or older Secondary Outcomes Prevalence of allergic sensitization (positive skin-prick test or specific IgE).	Risk Reduction Introducing peanuts at 4–11 months was associated with a 71% relative risk reduction in peanut allergy in populations with a high prevalence of the condition. Introducing eggs at 4–6 months was associated with a 40% relative risk reduction in egg allergy compared to later introduction. Found low-certainty evidence that early fish introduction (before 6–9 months) might be associated with a reduced risk of allergic rhinitis and sensitization. Breastfeeding review found no evidence that exclusive breastfeeding beyond 3–4 months protected against food allergy, eczema, or asthma.	Observational Data: Many included studies were observational, which are subject to biases, such as selection, information, and other confounding factors Self-Reporting Bias: data regarding the exact timing and quantity of food introduced relies on parental recall via questionnaires, which can lead to recall bias Lack of Standardization: combines many studies that may use different doses and forms of the allergens, making it difficult to determine what would be the minimum amount required to induce immune tolerance
Roberta Scarpone, Parisut Kimkool, Despo Ierodiakonou, et al. (2023)	Systematic Review & Meta-Analysis	Sample: 23 RCT studies identified from MEDLINE, EMBASE, and CENTRAL searched through December 2022 Inclusion Criteria RCTs evaluating the age of introduction for common allergenic foods (milk, egg, fish, shellfish, tree nuts, wheat, peanuts, and soya). Assessment of IgE-mediated food allergy between ages 1 and 5 years. Exclusion Criteria Studies where the “intervention” was maternal diet or breastfeeding duration rather than infant food introduction. Non-RCT studies	Primary Outcome Prevalence of IgE-mediated food allergy to a specific food at age 1 to 5 years, confirmed by oral food challenge or a combination of clinical history and sensitization. Secondary Outcomes Prevalence of “any food allergy” (allergy to any of the foods studied like eggs). Incidence of adverse events (anaphylaxis) during the introduction period	Risk Reduction  Introducing peanut at 4–6 months resulted in a 71% relative risk reduction in peanut allergy.  Introducing egg at 4–6 months resulted in a 30% relative risk reduction in egg allergy. ARR:  In a population with a 5% baseline prevalence of peanut allergy, early introduction would result in 35 fewer cases per 1000 infants. Other Food Introduction Early introduction of multiple foods simultaneously was shown to be an effective strategy for reducing the overall burden of food allergy.	Potential Biases: With RCTs, there is the possibility of selection, performance, detection, attrition, and reporting biases if there is a lack of randomization and/or blinding Adherence Issues: Several large trials struggled with low adherence, as parents found it difficult to feed infants high doses of multiple allergens consistently, which may dilute the observed effect.

 

Conclusions

Article 1 – Victoria X. Soriano, PhD, Rachel L. Peters, PhD, Margarita Moreno-Betancur, PhD, et a.l (2022)

• Early introduction of peanut (at or before 6 months of age) is associated with a significantly lower risk of developing a peanut allergy in infants with pre-existing eczema, with studies showing a nearly 50% reduction in allergy prevalence within this subgroup. For infants without eczema, the timing of introduction appears to have a much smaller effect on overall allergy risk. While early introduction is a safe and generally recommended practice for all infants, it should be prioritized as a high-value intervention for those with risk factors like eczema. Both early and late introduction strategies maintain similar safety profiles, providing clinicians and parents flexibility in timing; however, for the most effective prevention, the evidence supports a proactive approach in the first six months of life. 

Article 2 – George Du Toit, M. B., et al. (2015)

• For infants at high risk of developing a peanut allergy (has hx of severe eczema or egg allergy), the introduction of peanut protein between 4 and 11 months of age is an exceptionally effective preventative strategy. The LEAP trial provides evidence that early, regular consumption leads to an 80% or greater reduction in the prevalence of peanut allergy by age 5 compared to a strategy of strict avoidance. Clinicians should strongly encourage the introduction of age-appropriate peanut products (such as peanut butter or peanut puffs) early in infancy for high-risk children, ideally following an initial evaluation or skin-prick test to ensure it is safe to begin. 

Article 3 – Despo Ierodiakonou, Vanessa Garcia-Larsen, Andrew Logan, et al. (2016)

• In infants who are at high risk for food allergies (those with eczema, existing allergies, or both), introducing peanut and egg early (around 4–11 months) is a very effective way to prevent allergies. This systematic review and meta-analysis show moderate-certainty evidence that early and consistent exposure can reduce the risk of peanut allergy by about 70% and egg allergy by about 40% compared to avoiding these foods. The study supports the idea that there is a “window of opportunity” in early infancy when the immune system is more likely to develop tolerance to allergens. Because of this, clinicians should encourage introducing peanut and cooked egg once infants are ready for solid foods, typically around 4–6 months. While factors like severity of eczema and family history should still be considered, early introduction is now an important strategy to help reduce the risk of long-term food allergies.

Article 4 – Roberta Scarpone, Parisut Kimkool, Despo Ierodiakonou, et al. (2023)

• For infants at high risk of developing a peanut allergy (has hx of severe eczema or egg allergy), the introduction of peanut protein between 4 and 6 months of age is effective. Early, regular consumption leads to a 70% or greater reduction in the prevalence of peanut allergy compared to strict avoidance. Clinicians should prioritize the early introduction of both peanut and egg during the 4-to-6-month window as a foundational component of pediatric care. While the evidence for other allergens like milk and wheat is less definitive, the safety of early introduction is well-established, and the potential for a significant reduction in the overall burden of food allergy supports a proactive, diverse approach to infant feeding. Ultimately, implementing this strategy can fundamentally alter the trajectory of allergic disease for high-risk children.

Overall Conclusion

• Overall, based on these 4 studies, infants at high risk of developing food allergies, particularly those with severe eczema or pre-existing egg allergies, have a significant preventative benefit from the proactive introduction of allergenic proteins between 4 and 11 months of age. The studies consistently demonstrate that early, regular consumption of peanut and cooked egg leads to a 70% to 80% reduction in the prevalence of these allergies compared to strict avoidance. While early introduction is most effective for high-risk subgroups, it remains a safe and recommended practice for the general population to help foster oral tolerance during a critical “window of opportunity” in the immune system’s development. Ultimately, while early introduction is the more potent physiological strategy for allergy prevention, clinicians should still provide individualized guidance that accounts for a child’s skin health and parental readiness to maintain frequent exposure.

 

Clinical Bottom Line

Weight of the Evidence

Overall, the weight of the evidence provided by the 4 articles strongly supports the early introduction of peanut-containing foods between 4 and 11 months of age to reduce the risk of developing a peanut allergy. The highest-level evidence comes from the LEAP trial (Du Toit et al., 2015), a landmark randomized controlled trial (RCT) that demonstrated a massive reduction in allergy prevalence among high-risk infants. This is strengthened by 2 systematic reviews and meta-analyses (Ierodiakonou et al., 2016 and Scarpone et al., 2023). The Scarpone review synthesizes 23 RCTs involving over 13,000 participants, providing great evidence for peanut and egg introduction. While the cohort study by Soriano et al. (2022) showed that population-wide prevalence did not shift overnight despite guideline changes, it confirmed that on an individual level, early introduction remains a significant protective factor for infants with eczema.

Magnitude of Any Effects

The magnitude of effects observed across studies were highly consistent. In terms of peanut allergies, the LEAP trial found that among infants with no initial sensitivity, early consumption reduced allergy development by 86.1% (1.9% vs. 13.7% in the avoidance group). For those already sensitized, the risk was still reduced by 70%. The meta-analyses confirm this, showing a relative risk reduction (RRR) of approximately 71% (RR 0.29). In terms of the secondary outcomes of egg allergies, earlier introduction (4–6 months) was associated with a 30% to 40% reduction in developing an egg allergy too. Population-wise, in a population with a 5% baseline prevalence of peanut allergy, early introduction is estimated to result in 35 fewer cases per 1,000 infants. In the Australian cohort, early introduction for infants with eczema was associated with an adjusted odds ratio of 0.46, meaning a more than 50% reduction in the odds of developing the allergy compared to later introduction.

Clinical Significance

The prevalence of pediatric food allergies has increased significantly over the past few decades, creating a major challenge for both clinicians and families as it carries into adulthood. In the past, it was recommended to delay introducing highly allergenic foods like peanuts and eggs until later in childhood to protect the immune system. However, newer evidence suggests that this approach may have actually contributed to the rise in allergies. Current research supports the idea that there is a “window of opportunity” during the first year of life when the immune system is more likely to develop tolerance to allergens through early exposure. The LEAP trial (Du Toit et al., 2015), along with systematic reviews by Ierodiakonou et al. (2016) and Scarpone et al. (2023), and a cohort study by Soriano et al. (2022) helps to support this claim. The LEAP trial provides some of the strongest evidence, showing that early and regular peanut consumption in high-risk infants reduced the development of peanut allergy by over 80%. The systematic reviews support these findings, showing consistent evidence that introducing peanut and egg around 4–6 months lowers the risk of developing these allergies. However, the evidence is less clear for other foods like milk and wheat. Another important thing to consider is the role of eczema and other atopic conditions (e.g, hx of egg allergy). Infants with severe eczema are at higher risk because allergens can enter through the skin before they are introduced orally, increasing the chance of sensitization. In these high-risk infants, early oral introduction is especially beneficial and can significantly reduce allergy risk. While the benefit is smaller in infants without eczema, early introduction is still considered safe. Overall, current evidence supports introducing peanut and well-cooked egg as soon as infants are ready for solid foods, typically around 4–6 months. Delaying these foods beyond the first year is now thought to increase the risk of allergy, especially in high-risk children. Although recommendations should still be individualized based on each child and family, early introduction is an important, evidence-based strategy that can help reduce the overall burden of food allergies.

Other Considerations Important in Weighing This Evidence

Although the evidence supports early allergen introduction as a strategy to reduce the risk of food allergies, there are several important limitations and considerations. Adherence is a significant challenge  as many families struggle to maintain the frequency and quantity of allergen exposure required by protocols such as the LEAP study, highlighting the need for clinicians to provide realistic and practical guidance. Also, variability in outcomes across populations has been observed, with some studies suggesting reduced efficacy in certain ancestry groups, indicating that genetic or environmental factors may influence response to early introduction. Safety is another concern, as high-risk infants often require screening, such as skin-prick testing, before introduction to avoid adverse reactions in those already sensitized. Future research should focus on improving adherence strategies, expanding evidence to additional allergens, and standardizing introduction protocols to enhance generalizability and clinical implementation.

Article PDFs